RxSight Q4 revenue ~$8.4M (+71% YoY); full year 2021 revenue ~$22.6M (+54% YoY)

RxSight, Inc.

2021-FY EPS reported -$3.57 revenue$22,593,000

Q4 2021 revenue ~$8.4M, up 71% YoY; sold 45 LDDs (installed base 206) and 2,959 LALs.
FY 2021 revenue ~$22.6M, up 54% YoY; 114 LDDs and 8,328 LALs sold.
Cash, equivalents and short-term investments ~$159.3M as of Dec 31, 2021.
CEO Ron Kurtz cites continued adoption and ActivShield rollout as growth drivers for 2022.
Results are preliminary; audited Q4 and FY 2021 results expected in early March.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.